Valeant Pharmaceuticals Intl Inc (TSE:VRX)‘s stock had its “sector perform” rating reaffirmed by investment analysts at Royal Bank Of Canada in a report released on Tuesday.

Other equities analysts have also issued reports about the company. TD Securities decreased their price objective on Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a report on Wednesday, June 8th. Scotiabank cut their target price on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating for the company in a research report on Monday, July 25th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Valeant Pharmaceuticals Intl currently has an average rating of “Hold” and a consensus target price of C$38.83.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 35.82 on Tuesday. The stock’s market cap is $12.45 billion. Valeant Pharmaceuticals Intl has a 52-week low of $24.32 and a 52-week high of $299.06. The firm’s 50-day moving average price is $36.04 and its 200 day moving average price is $38.29.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.